
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: <em>Gastroenterology</em> 2025;168:267–284  </li>
<li style="margin-left: 0px;">Topic: Hepatitis B virus reactivation (HBVr) risk stratification and antiviral prophylaxis  </li>
<li style="margin-left: 0px;">Author(s): Faisal S. Ali, Mindie H. Nguyen, Ruben Hernaez, Daniel Q. Huang, Julius Wilder, Alejandro Piscoya, Tracey G. Simon, Yngve Falck-Ytter  </li>
</ul>
<details><summary><strong>1. Definitions and Risk Stratification Framework  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">HBVr defined as: <em>de novo</em> HBV-DNA detection OR ≥10-fold ↑ in HBV-DNA vs baseline  </li>
<li style="margin-left: 0px;">Permissible surrogates: new HBsAg or HBeAg detection  </li>
<li style="margin-left: 0px;">Hepatitis flare due to HBVr = <em>ALT ≥3× baseline</em> (minimum above reference range)  </li>
<li style="margin-left: 0px;">Baseline risk of HBVr = reactivation rate in exposed individuals <em>not</em> on prophylaxis  </li>
<li style="margin-left: 0px;">Risk categories:  </li>
<li style="margin-left: 20px;"><strong>Low risk</strong>: &lt;1% baseline HBVr  </li>
<li style="margin-left: 20px;"><strong>Moderate risk</strong>: 1%–10% baseline HBVr  </li>
<li style="margin-left: 20px;"><strong>High risk</strong>: &gt;10% baseline HBVr  </li>
<li style="margin-left: 0px;">Risk categorization based on:  </li>
<li style="margin-left: 20px;">Serologic status (HBsAg ± anti-HBc)  </li>
<li style="margin-left: 20px;">Immunosuppressive exposure type, dose, duration  </li>
<li style="margin-left: 0px;">Risk estimates derived from: RCT control arms (for high-certainty exposures) or observational studies (with strict inclusion criteria)  </li>
</ul>
</div></details>
<details><summary><strong>2. Evidence on Antiviral Prophylaxis Efficacy  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Pooled analysis of 12 RCTs (<em>n</em> = 879):  </li>
<li style="margin-left: 20px;">Antiviral prophylaxis → <em>RR 0.18</em> `<code style="background-color: #fff5b1; padding: 2px 4px; border-radius: 3px; font-family: monospace; border-bottom: 1px solid #ffe082;">[0.11–0.30]</code>` for HBVr vs monitoring  </li>
<li style="margin-left: 20px;">Absolute risk ↓: <strong>410 fewer HBVr cases / 1000</strong> at 50% baseline risk  </li>
<li style="margin-left: 0px;">Pooled analysis of 9 RCTs (<em>n</em> = 624):  </li>
<li style="margin-left: 20px;">Antiviral prophylaxis → <em>RR 0.22</em> `<code style="background-color: #fff5b1; padding: 2px 4px; border-radius: 3px; font-family: monospace; border-bottom: 1px solid #ffe082;">[0.10–0.50]</code>` for hepatitis flare  </li>
<li style="margin-left: 20px;">Absolute risk ↓: <strong>390 fewer flares / 1000</strong> at 50% baseline risk  </li>
<li style="margin-left: 0px;">Chemotherapy interruption: <em>RR 0.31</em> `<code style="background-color: #fff5b1; padding: 2px 4px; border-radius: 3px; font-family: monospace; border-bottom: 1px solid #ffe082;">[0.05–1.84]</code>` (very low certainty)  </li>
<li style="margin-left: 0px;">Adverse events: <em>RR 1.08</em> `<code style="background-color: #fff5b1; padding: 2px 4px; border-radius: 3px; font-family: monospace; border-bottom: 1px solid #ffe082;">[0.47–2.49]</code>` (low certainty)  </li>
<li style="margin-left: 0px;">High barrier-to-resistance antivirals assumed for all recommendations  </li>
<li style="margin-left: 0px;">Duration: ≥6 months after stopping most immunosuppressants; <strong>≥12 months for B-cell–depleting agents</strong>  </li>
</ul>
</div></details>
<details><summary><strong>3. Exposure-Specific Risk Categorization and Recommendations  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>High-Risk Exposures (&gt;10% baseline HBVr)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>HBsAg-positive individuals</strong>:  </li>
<li style="margin-left: 20px;">Anthracyclines (e.g., doxorubicin)  </li>
<li style="margin-left: 20px;">B-cell–depleting agents (rituximab, ofatumumab)  </li>
<li style="margin-left: 20px;">Anti–TNF agents (infliximab, adalimumab)  </li>
<li style="margin-left: 20px;">CAR-T therapy  </li>
<li style="margin-left: 20px;">Cytokine/integrin inhibitors (ustekinumab, secukinumab)  </li>
<li style="margin-left: 20px;">Anti-IL6 agents (tocilizumab)  </li>
<li style="margin-left: 20px;">JAK inhibitors (tofacitinib, baricitinib)  </li>
<li style="margin-left: 20px;">TACE  </li>
<li style="margin-left: 20px;">HCV co-infection + DAA therapy  </li>
<li style="margin-left: 0px;"><strong>Recommendation</strong>: Strong recommendation for antiviral prophylaxis  </li>
</ul>
</div></details>
<details><summary><strong>Moderate-Risk Exposures (1%–10% baseline HBVr)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>HBsAg-negative/anti-HBc–positive individuals</strong>:  </li>
<li style="margin-left: 20px;">Anthracyclines  </li>
<li style="margin-left: 20px;">ICIs (nivolumab, pembrolizumab, ipilimumab)  </li>
<li style="margin-left: 20px;">Anti–T-cell therapy (abatacept)  </li>
<li style="margin-left: 20px;">TKIs (imatinib, sunitinib)  </li>
<li style="margin-left: 20px;">Cytokine/integrin inhibitors  </li>
<li style="margin-left: 20px;">CAR-T therapy  </li>
<li style="margin-left: 20px;">Anti-IL6 agents  </li>
<li style="margin-left: 20px;">JAK inhibitors  </li>
<li style="margin-left: 20px;">TACE  </li>
<li style="margin-left: 20px;">Corticosteroids: moderate/high dose × ≥4 weeks  </li>
<li style="margin-left: 0px;"><strong>Recommendation</strong>: Conditional recommendation for antiviral prophylaxis; monitoring acceptable if patient values prioritize avoiding long-term therapy  </li>
</ul>
</div></details>
<details><summary><strong>Low-Risk Exposures (&lt;1% baseline HBVr)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>All serologic groups</strong>:  </li>
<li style="margin-left: 20px;">Methotrexate, 6-MP, azathioprine (monotherapy)  </li>
<li style="margin-left: 20px;">Intra-articular steroid injection  </li>
<li style="margin-left: 20px;">Corticosteroids: low dose (&lt;10 mg prednisone eq) × ≥4 weeks (HBsAg-negative only)  </li>
<li style="margin-left: 20px;">Corticosteroids: low/moderate/high dose × &lt;1 week (all groups)  </li>
<li style="margin-left: 20px;">Anti–TNF agents (HBsAg-negative/anti-HBc–positive)  </li>
<li style="margin-left: 20px;">ICIs (HBsAg-negative/anti-HBc–positive)  </li>
<li style="margin-left: 20px;">HCV co-infection + DAA (HBsAg-negative/anti-HBc–positive)  </li>
<li style="margin-left: 0px;"><strong>Recommendation</strong>: Conditional recommendation for monitoring alone; antiviral prophylaxis acceptable if patient values prioritize avoiding small reactivation risk  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Screening, Testing, and Implementation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Universal HBV screening recommended for all adults ≥18 y</strong> (CDC 2023):  </li>
<li style="margin-left: 20px;">Test for HBsAg, anti-HBs, total anti-HBc  </li>
<li style="margin-left: 0px;"><strong>Stratified screening by HBVr risk <em>no longer needed</strong></em> due to universal CDC guidance  </li>
<li style="margin-left: 0px;"><strong>Testing algorithm</strong>:  </li>
<li style="margin-left: 20px;">Initial: HBsAg + anti-HBc (minimum)  </li>
<li style="margin-left: 20px;">If positive: add anti-HBs and HBV-DNA  </li>
<li style="margin-left: 0px;"><strong>Monitoring protocol for those on antiviral prophylaxis <em>omission</strong></em>:  </li>
<li style="margin-left: 20px;">Every 1–3 months  </li>
<li style="margin-left: 20px;">Must include HBV-DNA <em>and</em> ALT  </li>
<li style="margin-left: 0px;"><strong>Special considerations</strong>:  </li>
<li style="margin-left: 20px;">Anti-HBs positivity does <em>not</em> mitigate HBVr risk (pooled proportion anti-HBs+ in controls = 65% `<code style="background-color: #fff5b1; padding: 2px 4px; border-radius: 3px; font-family: monospace; border-bottom: 1px solid #ffe082;">[58%–72%]</code>`)  </li>
<li style="margin-left: 20px;">Vedolizumab: insufficient evidence for risk categorization (1 case reported w/ concomitant steroids + azathioprine)  </li>
<li style="margin-left: 20px;">DAA therapy in HBsAg-positive/HCV co-infection: extend antiviral prophylaxis to <strong>6–12 months after DAA completion</strong> (per 1 RCT showing &gt;90% HBVr post-entecavir cessation at 12 weeks)</li>
</ul>
</div></details>
<details><summary><strong>5. Duration of Antiviral Prophylaxis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Pooled analysis of 3 RCTs comparing longer vs shorter prophylaxis duration:  </li>
<li style="margin-left: 20px;">RR for HBVr = <em>0.99</em> `<code style="background-color: #fff5b1; padding: 2px 4px; border-radius: 3px; font-family: monospace; border-bottom: 1px solid #ffe082;">[0.76–1.28]</code>`  </li>
<li style="margin-left: 20px;">RR for hepatitis flare = <em>1.24</em> `<code style="background-color: #fff5b1; padding: 2px 4px; border-radius: 3px; font-family: monospace; border-bottom: 1px solid #ffe082;">[0.46–3.39]</code>`  </li>
<li style="margin-left: 20px;">Certainty downgraded to <em>low</em> due to very serious imprecision  </li>
<li style="margin-left: 0px;">Subgroup analysis: 12 months vs 6 months continuation post-exposure cessation:  </li>
<li style="margin-left: 20px;">RR for HBVr = <em>1.07</em> `<code style="background-color: #fff5b1; padding: 2px 4px; border-radius: 3px; font-family: monospace; border-bottom: 1px solid #ffe082;">[0.68–1.68]</code>`  </li>
<li style="margin-left: 20px;">RR for hepatitis flare = <em>1.35</em> `<code style="background-color: #fff5b1; padding: 2px 4px; border-radius: 3px; font-family: monospace; border-bottom: 1px solid #ffe082;">[0.45–3.99]</code>`  </li>
<li style="margin-left: 0px;">Panel conclusion:  </li>
<li style="margin-left: 20px;">Minimum duration = <strong>≥6 months</strong> after stopping most immunosuppressants  </li>
<li style="margin-left: 20px;">Extension to <strong>12 months reasonable for high-risk exposures</strong>  </li>
<li style="margin-left: 20px;"><strong>≥12 months mandatory for B-cell–depleting agents</strong> (e.g., rituximab) due to delayed HBVr cases beyond 12 months  </li>
</ul>
</div></details>
<details><summary><strong>6. Cost-Effectiveness and Equity Considerations  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Cost-Effectiveness Analysis (CEA)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">No direct CEAs for low/moderate/high risk categories identified  </li>
<li style="margin-left: 0px;">Fujita et al CEA (moderate-risk exposure baseline risk = 6%):  </li>
<li style="margin-left: 20px;">Incremental cost-effectiveness ratio (ICER) = <strong>US$132,048 / QALY</strong>  </li>
<li style="margin-left: 20px;">Willingness-to-pay threshold = <strong>US$45,662</strong> (converted from Japanese yen)  </li>
<li style="margin-left: 0px;">Model limitation: assumed HBVr risk <em>with</em> prophylaxis = 2.1%  </li>
<li style="margin-left: 20px;">Corrected estimate: <em>2.1% × (1 – 0.82) = 0.378%</em>  </li>
<li style="margin-left: 20px;">Lower probability → lower ICER likely falling within <strong>$50,000–100,000 / QALY</strong> acceptable range  </li>
<li style="margin-left: 0px;">Extrapolation:  </li>
<li style="margin-left: 20px;">Antiviral prophylaxis likely <em>cost-effective for high-risk</em> cases  </li>
<li style="margin-left: 20px;">May be <em>cost-effective for moderate-risk</em> after model correction  </li>
<li style="margin-left: 20px;">Likely <em>not cost-effective for low-risk</em> cases (trivial benefit, ongoing drug costs)  </li>
<li style="margin-left: 0px;">Panel conclusion: Formal CEAs stratified by risk category needed  </li>
</ul>
</div></details>
<details><summary><strong>Equity Considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Additional Health Disparities and Minority Health Search Strategy conducted  </li>
<li style="margin-left: 0px;">No potential equity issues identified from guideline recommendations  </li>
<li style="margin-left: 0px;">Antivirals covered by most insurance plans, but out-of-pocket costs may act as barrier  </li>
<li style="margin-left: 0px;">Tenofovir alafenamide preferred over tenofovir disoproxil fumarate due to:  </li>
<li style="margin-left: 20px;">No adverse impact on renal function  </li>
<li style="margin-left: 20px;">No adverse impact on bone mineral density  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>7. Serologic Modifiers of HBVr Risk  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Anti-HBs Status and Risk Mitigation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">4 RCTs reported anti-HBs status in control arms: pooled proportion anti-HBs+ = <strong>65%</strong> `<code style="background-color: #fff5b1; padding: 2px 4px; border-radius: 3px; font-family: monospace; border-bottom: 1px solid #ffe082;">[58%–72%]</code>`  </li>
<li style="margin-left: 0px;">Combined meta-analysis (RCTs + nonrandomized studies) of rituximab-exposed patients:  </li>
<li style="margin-left: 20px;">Baseline HBVr risk for anti-HBs+ individuals = <strong>6.6%</strong>  </li>
<li style="margin-left: 20px;">Upper bound of 95% CI = <strong>14.4%</strong>  </li>
<li style="margin-left: 0px;">Panel conclusion: anti-HBs positivity <em>does not mitigate HBVr risk</em>  </li>
<li style="margin-left: 20px;">Anti-HBs status should <em>not</em> be used to guide prophylaxis decisions  </li>
</ul>
</div></details>
<details><summary><strong>Serologic Risk Modulation by Exposure Type  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>HBsAg-positive vs anti-HBc–positive/HBsAg-negative</strong>:  </li>
<li style="margin-left: 20px;">Baseline risk consistently higher in HBsAg+ across all exposures (e.g., anti–TNF: 332/1000 vs 2/1000)  </li>
<li style="margin-left: 0px;"><strong>Key exceptions with uncertainty</strong>:  </li>
<li style="margin-left: 20px;">Abatacept in HBsAg+ individuals: observed risk &lt;0.1% but upper 95% CI = <strong>44/1000</strong> → panel classified as <em>moderate-risk</em> based on biological plausibility  </li>
<li style="margin-left: 20px;">CAR-T in HBsAg+ individuals: no direct data → panel classified as <em>high-risk</em> based on background immunosuppression and co-therapies  </li>
<li style="margin-left: 20px;">Vedolizumab: insufficient evidence (1 case w/ concomitant immunomodulators)  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Knowledge Gaps and Future Research Priorities  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Evidence Deficiencies Identified  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>High uncertainty risk categories</strong>:  </li>
<li style="margin-left: 20px;">Anti-HBs status not used for risk stratification despite high prevalence in controls  </li>
<li style="margin-left: 20px;">Vedolizumab: single HBVr case w/ confounding immunomodulators  </li>
<li style="margin-left: 20px;">Anti-IL6 in HBsAg+ individuals: no unprophylaxed cohort data  </li>
<li style="margin-left: 20px;">TKI in anti-HBc+ individuals: observed risk &lt;0.1% but upper 95% CI = <strong>22/1000</strong>  </li>
<li style="margin-left: 0px;"><strong>Duration uncertainty</strong>:  </li>
<li style="margin-left: 20px;">No RCTs directly comparing optimal prophylaxis duration across exposure classes  </li>
<li style="margin-left: 20px;">Current recommendations extrapolated from limited RCTs (3 total)  </li>
</ul>
</div></details>
<details><summary><strong>Recommended Research Priorities  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Maintain national registries with:  </li>
<li style="margin-left: 20px;">Baseline HBV serologies (HBsAg, anti-HBc, anti-HBs)  </li>
<li style="margin-left: 20px;">Clear HBVr definition (viral load + ALT criteria)  </li>
<li style="margin-left: 20px;">Nonselective cohort enrollment  </li>
<li style="margin-left: 0px;">Develop online repository updated periodically with:  </li>
<li style="margin-left: 20px;">Exposure-specific baseline HBVr estimates  </li>
<li style="margin-left: 20px;">Risk modification by serology, dose, duration  </li>
<li style="margin-left: 0px;">Prioritize studies on:  </li>
<li style="margin-left: 20px;">Long-term antiviral prophylaxis duration (e.g., &gt;12 months for high-risk)  </li>
<li style="margin-left: 20px;">Cost-effectiveness stratified by risk category  </li>
<li style="margin-left: 20px;">Equity-focused implementation research (e.g., access barriers to antivirals)  </li>
<li style="margin-left: 0px;">Address gaps in:  </li>
<li style="margin-left: 20px;">Gut-specific anti–T cell agents (vedolizumab)  </li>
<li style="margin-left: 20px;">Novel immunotherapies (e.g., bispecific antibodies, novel CAR-T constructs)  </li>
<li style="margin-left: 20px;">Pediatric populations (current evidence adult-only)</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9. Clinical Decision Support and Implementation Tools  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Recommendation Summary Table (Adapted from Table 4)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Recommendation 1</strong>: For individuals at high risk of HBVr, the AGA recommends antiviral prophylaxis over monitoring alone  </li>
<li style="margin-left: 20px;"><em>Strong recommendation</em>, moderate certainty evidence  </li>
<li style="margin-left: 20px;">Antivirals must have high barrier to resistance (e.g., entecavir, tenofovir alafenamide)  </li>
<li style="margin-left: 20px;">Initiate <em>before</em> immunosuppression; continue ≥6 months post-therapy (≥12 months for B-cell–depleting agents)  </li>
<li style="margin-left: 0px;"><strong>Recommendation 2</strong>: For individuals at moderate risk of HBVr, the AGA suggests antiviral prophylaxis over monitoring alone  </li>
<li style="margin-left: 20px;"><em>Conditional recommendation</em>, moderate certainty evidence  </li>
<li style="margin-left: 20px;">Monitoring acceptable if patient values prioritize avoiding long-term antiviral use and cost, <em>provided</em> adherence to 1–3 monthly monitoring (HBV-DNA + ALT)  </li>
<li style="margin-left: 0px;"><strong>Recommendation 3</strong>: For individuals at low risk of HBVr, the AGA suggests monitoring alone over antiviral prophylaxis  </li>
<li style="margin-left: 20px;"><em>Conditional recommendation</em>, moderate certainty evidence  </li>
<li style="margin-left: 20px;">Antiviral prophylaxis acceptable if patient values prioritize avoiding small reactivation risk (e.g., multiple low-risk immunosuppressants)  </li>
<li style="margin-left: 0px;"><strong>Recommendation 4</strong>: For individuals at potential risk of HBVr, the AGA recommends testing for hepatitis B  </li>
<li style="margin-left: 20px;"><em>Strong recommendation</em>, moderate certainty evidence  </li>
<li style="margin-left: 20px;">Universal CDC screening (HBsAg, anti-HBs, total anti-HBc) for all adults ≥18 y obviates risk-stratified screening  </li>
<li style="margin-left: 20px;">Initial test: HBsAg + anti-HBc (minimum); if positive, add anti-HBs and HBV-DNA  </li>
</ul>
</div></details>
<details><summary><strong>Clinical Decision Support Tool (Figure 2 Summary)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Algorithm flow</strong>:  </li>
<li style="margin-left: 20px;">Step 1: Confirm HBV serologic status (HBsAg, anti-HBc, anti-HBs)  </li>
<li style="margin-left: 20px;">Step 2: Identify immunosuppressive exposure (see Tables 5–6)  </li>
<li style="margin-left: 20px;">Step 3: Assign risk category based on exposure × serology matrix (Table 6)  </li>
<li style="margin-left: 20px;">Step 4: Apply recommendation (1–3) with shared decision-making where conditional  </li>
<li style="margin-left: 0px;"><strong>Risk matrix highlights</strong>:  </li>
<li style="margin-left: 20px;"><em>High-risk combinations</em>: HBsAg+ × any immunosuppressant (except low-dose steroids &lt;1 week)  </li>
<li style="margin-left: 20px;"><em>Moderate-risk combinations</em>: HBsAg–/anti-HBc+ × moderate/high-dose steroids ≥4 weeks, ICIs, TKIs, CAR-T  </li>
<li style="margin-left: 20px;"><em>Low-risk combinations</em>: anti-HBc– × any exposure; low-dose steroids &lt;1 week or ≥4 weeks (HBsAg– only)  </li>
<li style="margin-left: 0px;"><strong>Special cases</strong>:  </li>
<li style="margin-left: 20px;"><em>Corticosteroid dose/duration interplay</em>:  </li>
<li style="margin-left: 40px;">High-dose (&gt;20 mg prednisone eq) × ≥4 weeks → high-risk if HBsAg+, moderate-risk if HBsAg–/anti-HBc+  </li>
<li style="margin-left: 40px;">Moderate-dose (10–20 mg) × ≥4 weeks → moderate-risk for both serologies  </li>
<li style="margin-left: 40px;">Low-dose (&lt;10 mg) × ≥4 weeks → moderate-risk if HBsAg+/anti-HBc–, low-risk if HBsAg–  </li>
<li style="margin-left: 40px;">Any dose × &lt;1 week → low-risk for all serologies  </li>
<li style="margin-left: 20px;"><em>Combination immunosuppression</em>: Risk may exceed single-agent estimates (e.g., rituximab + corticosteroids)  </li>
<li style="margin-left: 20px;"><em>HCV co-infection</em>: DAA therapy unmasked HBVr in occult infection → risk depends on baseline HBsAg status  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10. Grading of Evidence and Certainty Assessment  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>GRADE Framework Application  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Certainty assessment domains</strong>:  </li>
<li style="margin-left: 20px;">Risk of bias (Cochrane RoB 2.0 for RCTs)  </li>
<li style="margin-left: 20px;">Inconsistency (I² statistic + visual forest plots)  </li>
<li style="margin-left: 20px;">Indirectness (population, intervention, outcome mismatches)  </li>
<li style="margin-left: 20px;">Imprecision (95% CI crossing clinically important thresholds: 1% and 10%)  </li>
<li style="margin-left: 20px;">Publication bias (funnel plots + Egger test not feasible due to few studies)  </li>
<li style="margin-left: 20px;">Large effect estimate (e.g., RR &lt;0.5 for benefits)  </li>
<li style="margin-left: 0px;"><strong>Evidence profiles generated per outcome</strong> (Tables 2–3):  </li>
<li style="margin-left: 20px;"><em>HBVr</em>: moderate certainty (⨁⨁⨁/)  </li>
<li style="margin-left: 40px;">Downgraded for imprecision in high-risk estimates (e.g., ICIs: upper 95% CI crossed 10% threshold)  </li>
<li style="margin-left: 20px;"><em>Hepatitis flare</em>: moderate certainty (⨁⨁⨁/)  </li>
<li style="margin-left: 40px;">Fragility Index = 5 (indicates fragile result)  </li>
<li style="margin-left: 20px;"><em>Chemotherapy interruption</em>: very low certainty (⨁///)  </li>
<li style="margin-left: 40px;">CI crossed clinically important threshold (RR 0.31 `<code style="background-color: #fff5b1; padding: 2px 4px; border-radius: 3px; font-family: monospace; border-bottom: 1px solid #ffe082;">[0.05–1.84]</code>`)  </li>
<li style="margin-left: 20px;"><em>Adverse events</em>: low certainty (⨁⨁//)  </li>
<li style="margin-left: 40px;">Wide CI including both harm and benefit (<em>RR 1.08</em> `<code style="background-color: #fff5b1; padding: 2px 4px; border-radius: 3px; font-family: monospace; border-bottom: 1px solid #ffe082;">[0.47–2.49]</code>`)  </li>
</ul>
</div></details>
<details><summary><strong>Baseline Risk Estimation Methodology  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>RCT-derived baseline risks</strong>:  </li>
<li style="margin-left: 20px;">Pooled using inverse-variance random-effects model (STATA)  </li>
<li style="margin-left: 20px;">Applied to varying baseline risks to compute absolute risk differences (Table 5)  </li>
<li style="margin-left: 0px;"><strong>Observational study-derived baseline risks</strong>:  </li>
<li style="margin-left: 20px;">Inclusion criteria:  </li>
<li style="margin-left: 40px;">Consecutive at-risk cohort <em>not</em> on prophylaxis  </li>
<li style="margin-left: 40px;">Appropriate baseline serology (HBsAg, anti-HBc)  </li>
<li style="margin-left: 40px;">HBVr definition aligned with panel criteria  </li>
<li style="margin-left: 40px;">Follow-up duration covering exposure period or 1 year  </li>
<li style="margin-left: 20px;">Excluded: case series without denominator, case reports, case-control studies  </li>
<li style="margin-left: 20px;">Analysis: inverse-variance fixed-effects model + Freeman-Tukey double arcsine transformation  </li>
<li style="margin-left: 0px;"><strong>Class effect assumption</strong>: Risk estimates applied to entire drug class (e.g., TKI class risk used for all TKIs)  </li>
<li style="margin-left: 0px;"><strong>Uncertainty handling</strong>:  </li>
<li style="margin-left: 20px;">When 95% CI crosses risk thresholds → downgraded certainty (Figure 1)  </li>
<li style="margin-left: 20px;">Biological plausibility used to override statistical imprecision when evidence insufficient (e.g., abatacept in HBsAg+)  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>11. Limitations and Future Updates  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Documented Limitations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Evidence gaps</strong>:  </li>
<li style="margin-left: 20px;">No RCTs for most novel immunotherapies (e.g., bispecific antibodies, emerging CAR-T targets)  </li>
<li style="margin-left: 20px;">Pediatric populations excluded from all included studies  </li>
<li style="margin-left: 20px;">Limited data on HBVr with gut-specific anti–T cell agents (vedolizumab)  </li>
<li style="margin-left: 0px;"><strong>Methodological constraints</strong>:  </li>
<li style="margin-left: 20px;">Baseline risk estimates for moderate/low-risk categories often derived from observational data with residual confounding  </li>
<li style="margin-left: 20px;">Duration of prophylaxis recommendations extrapolated from limited RCTs (3 studies)  </li>
<li style="margin-left: 20px;">Cost-effectiveness analysis based on outdated assumptions (unadjusted HBVr risk in prophylaxis arm)  </li>
<li style="margin-left: 0px;"><strong>Clinical heterogeneity</strong>:  </li>
<li style="margin-left: 20px;">Variable HBVr definitions across studies (e.g., absolute HBV-DNA &gt;2000 IU/mL vs 10-fold ↑)  </li>
<li style="margin-left: 20px;">Heterogeneous antiviral regimens (entecavir vs lamivudine vs tenofovir)  </li>
<li style="margin-left: 20px;">Differing follow-up durations (1–10 years in anti–TNF studies)  </li>
</ul>
</div></details>
<details><summary><strong>Guideline Update Protocol  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Scheduled review</strong>: 5 years from publication (2030)  </li>
<li style="margin-left: 0px;"><strong>Trigger-based updates</strong>:  </li>
<li style="margin-left: 20px;">New high-quality RCTs for novel immunotherapies (e.g., JAK inhibitors in IBD)  </li>
<li style="margin-left: 20px;">Emergence of new risk-modifying factors (e.g., anti-HBs titer thresholds)  </li>
<li style="margin-left: 20px;">Changes in CDC screening guidelines or antiviral formulary (e.g., generic tenofovir alafenamide availability)  </li>
<li style="margin-left: 0px;"><strong>Continuous evidence monitoring</strong>:  </li>
<li style="margin-left: 20px;">Annual literature search using updated search strategy (Supplementary Table 1)  </li>
<li style="margin-left: 20px;">Health disparities and minority health search strategy integrated into annual update cycle  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>12. Implementation Considerations for Frontline Practitioners  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Serologic Testing Workflow  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Step 1: Universal screening</strong> (all adults ≥18 y):  </li>
<li style="margin-left: 20px;">Test HBsAg, anti-HBs, total anti-HBc (per CDC 2023)  </li>
<li style="margin-left: 0px;"><strong>Step 2: Reflex testing</strong>:  </li>
<li style="margin-left: 20px;">If HBsAg+ → order HBV-DNA and liver ultrasound  </li>
<li style="margin-left: 20px;">If anti-HBc+ (regardless of HBsAg) → order anti-HBs and HBV-DNA  </li>
<li style="margin-left: 20px;">If all negative → no further testing unless high-risk exposure (e.g., stem cell transplant)  </li>
<li style="margin-left: 0px;"><strong>Step 3: Risk categorization</strong>:  </li>
<li style="margin-left: 20px;">Cross-reference exposure (drug, procedure) with serology in Table 6  </li>
<li style="margin-left: 20px;">Adjust for dose/duration (e.g., corticosteroids: low/moderate/high × &lt;1 week vs ≥4 weeks)  </li>
<li style="margin-left: 20px;">Consider combination immunosuppression (e.g., methotrexate + anti–TNF → ↑ risk beyond monotherapy estimates)  </li>
</ul>
</div></details>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
